ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX): Examining Valuation After SEC Subpoena and Ongoing Legal Probes
Telix Pharmaceuticals (ASX:TLX) has disclosed that it received a subpoena from the U.S. Securities and Exchange Commission regarding statements about its prostate cancer therapeutics. This has prompted several law firms to investigate possible securities violations.
See our latest analysis for Telix Pharmaceuticals.
The pressure from regulatory scrutiny and legal investigations has weighed on Telix Pharmaceuticals’ momentum, with the share price dropping 33.9% year-to-date and the 1-year...